Clinical Data Lands Buyout as Forest Makes $1.2B Viibryd Bet
By Jennifer Boggs
Wednesday, February 23, 2011
Buyout speculation fueled by the late January approval of depression drug Viibryd (vilazodone) not to mention last week's chatter after President and CEO Drew Fromkin cancelled his presentation at BIO CEO ended Tuesday with a resounding thud, as Clinical Data Inc. disclosed an offer much lower than its bullish analysts had expected.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.